---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-029018"
form_type: "8-K"
ticker: "FEED"
cik: "0001326706"
company_name: "ENvue Medical, Inc."
filed_at: "2025-12-23T23:59:59+00:00"
generated_at: "2026-05-16T12:13:50.572858+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NanoVibronix amends CEO contract with 9% equity grant; appoints interim CFO

## Summary
- CEO Doron Besser new base salary $360K, bonus up to $180K; severance of 12 months' base salary on change-of-control termination.
- Besser receives 180,000 RSUs (9% of outstanding common stock) plus annual grants to maintain 9% equity.
- CFO Stephen Brown departed Dec. 18, 2025; Nicole Fernandez-McGovern appointed Interim CFO via consulting agreement with RCM Financial Consulting.
- Fernandez-McGovern receives $300K annual salary; served as CFO of NLS Pharmaceutics and interim CFO of Hayden AI.

## SEC filing metadata
- accession: 0001493152-25-029018
- form_type: 8-K
- ticker: FEED
- cik: 0001326706
- company_name: ENvue Medical, Inc.
- filed_at: 2025-12-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326706/000149315225029018/0001493152-25-029018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326706/000149315225029018/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-029018
- JSON: https://secwatch.observer/filing/0001493152-25-029018.json
- Plain text: https://secwatch.observer/filing/0001493152-25-029018.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.